



PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
22124SERIAL NO.  
10/622,231

## LIST OF PRIOR ART CITED BY APPLICANT

APPLICANT Changgeng Ruan

FILING DATE  
07/17/2003GROUP  
1641

## U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,387,413	02/07/1995	COLLER, Barry S.			
	A2						
	A3						
	A4						
	A5						
	A6						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>JZB</i>	A7	EP557535B1	12/17/1997	EP			
<i>JZB</i>	A8	CA1297816	03/24/1992	CA			
	A9						
	A10						
	A11						

## OTHER PRIOR ART (Including Author, Title, Pertinent Pages, Etc.)

<i>JZB</i>	A12	BECKER, Richard C., <i>Thrombin Antagonists and Antiplatelet Agents</i> , Am J Cardiol 1932;69:39A-51A
<i>JZB</i>	A13	COLLER, Barry S., <i>Progress in Hemostasis and Thrombosis</i> , 1989; Vol 9:117-124
<i>JZB</i>	A14	KNIGHT, David M., et al, <i>The Immunogenicity of the 7E3 Murine Monoclonal FAB Antibody Fragment Variable Region is Dramatically Reduced in Humans by Substitution of Human for Murine Constant Regions</i> , Molecular Immunology, Vol 32, No. 16, pp. 1271-1281, 1995
<i>JZB</i>	A15	VERSTRAETE, Marc, <i>Synthetic Inhibitors of Platelet Glycoprotein IIb/IIIa In Clinical Development</i> , Circulation, 2000;102:e76-e80
<i>JZB</i>	A16	CHANGGENG, Ruan, <i>Monoclonal Antibodies and Thrombotic Diseases</i> , Science and Technology at the Frontier in China, [Ed. By Chinese Engineering Academy] 2001; Vol 4: 131-145
<i>JZB</i>	A17	COLLER, Barry S., et al, <i>A Murine Monoclonal Antibody That Completely Blocks the Binding of Fibrinogen to Platelets Produces a Thrombasthenic-like State in Normal Platelets and Binds to Glycoproteins IIb and/or IIIa</i> , J.Clin.Invest. 1983; Vol 72(1):325-338

EXAMINER

James L. Grun

DATE CONSIDERED

11/02/2004

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.